Duke logo

Medeor MDR-101-MLK - Clinical Trial

Age Group
Adults

Study Details

Full Title
MDR-101-MLK: A Phase 3 Prospective, randomized, multi-center, open-label, controlled trial to assess the efficacy and safety of cellular immunotherapy with MDR-101 for induction of immune tolerance in recipients of HLA-matched, living donor kidney transpla
Principal Investigator
Kidney/Pancreas Transplant Surgeon
Protocol Number
IRB:PRO00087585
NCT:NCT03363945
Phase
Phase III
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698